- Report
- February 2025
- 200 Pages
Global
From €4115EUR$4,490USD£3,460GBP
- Report
- January 2025
- 375 Pages
Global
From €4582EUR$5,000USD£3,853GBP
- Report
- February 2025
- 150 Pages
Global
From €2978EUR$3,250USD£2,505GBP
€4445EUR$4,850USD£3,738GBP
- Report
- November 2024
- 150 Pages
Global
From €2978EUR$3,250USD£2,505GBP
€4445EUR$4,850USD£3,738GBP
- Report
- April 2025
- 175 Pages
Global
From €4115EUR$4,490USD£3,460GBP
- Report
- May 2025
- 134 Pages
Global
From €2748EUR$2,999USD£2,311GBP
- Report
- April 2025
- 200 Pages
Global
From €7285EUR$7,950USD£6,127GBP
- Drug Pipelines
- April 2025
- 100 Pages
Global
From €2749EUR$3,000USD£2,312GBP
- Drug Pipelines
- April 2025
- 60 Pages
Global
From €1146EUR$1,250USD£963GBP
- Drug Pipelines
- July 2024
- 150 Pages
Global
From €3437EUR$3,750USD£2,890GBP
- Report
- May 2025
- 181 Pages
Global
From €4124EUR$4,500USD£3,468GBP
- Report
- May 2025
- 180 Pages
Global
From €4124EUR$4,500USD£3,468GBP
- Report
- April 2025
- 189 Pages
Global
From €4124EUR$4,500USD£3,468GBP
- Report
- February 2025
- 182 Pages
Global
From €4124EUR$4,500USD£3,468GBP
- Report
- February 2025
- 183 Pages
Global
From €4124EUR$4,500USD£3,468GBP
- Report
- July 2024
- 200 Pages
Global
From €4535EUR$4,949USD£3,814GBP
- Report
- July 2021
Global
From €870EUR$949USD£731GBP
- Report
- July 2022
- 461 Pages
Global
From €4862EUR$5,491USD£3,950GBP
From €400EUR$468USD£348GBP
- Report
- October 2023
- 85 Pages
United States
From €4445EUR$4,850USD£3,738GBP

Adalimumab is a biologic drug used to treat a variety of immune disorders, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and juvenile idiopathic arthritis. It is a monoclonal antibody that works by blocking the action of tumor necrosis factor (TNF), a protein that plays a role in inflammation. Adalimumab is administered by subcutaneous injection and is available in both brand-name and generic forms.
Adalimumab is one of the most widely prescribed drugs for immune disorders, and it has been approved for use in more than 100 countries. It is a highly effective treatment for many of the conditions it is used to treat, and it has been shown to improve quality of life for patients.
Some of the companies in the Adalimumab market include AbbVie, Amgen, Biogen, Boehringer Ingelheim, Janssen Biotech, Merck, and Pfizer. Show Less Read more